Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)
China · Delayed Price · Currency is CNY 49.80
+3.18 (6.82%)
Sep 30, 2026, 3:00 PM CST
Hangzhou Alltest Biotech Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 3,775 | 5,003 | 4,909 | 5,362 | 5,519 | 6,631 | |
Market Cap Growth | -27.97% | 1.91% | -8.43% | -2.86% | -16.76% | - |
Enterprise Value | 1,657 | 2,552 | 2,259 | 2,648 | 2,003 | 4,130 |
Last Close Price | 49.80 | 62.54 | 59.72 | 61.43 | 57.06 | 65.24 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 28.44 | 22.72 | 16.23 | 29.69 | 4.66 | 8.66 |
PS Ratio | 4.35 | 5.53 | 5.67 | 7.10 | 1.63 | 3.54 |
PB Ratio | 1.00 | 1.27 | 1.26 | 1.40 | 1.32 | 2.03 |
P/TBV Ratio | 1.04 | 1.31 | 1.30 | 1.44 | 1.36 | 2.04 |
P/FCF Ratio | 66.08 | - | 45.10 | - | 5.06 | 8.46 |
P/OCF Ratio | 19.05 | 24.22 | 14.90 | 216.51 | 4.06 | 7.18 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.91 | 2.82 | 2.61 | 3.51 | 0.59 | 2.21 |
EV/EBITDA Ratio | 9.75 | 11.83 | 8.48 | 22.03 | 1.45 | 4.88 |
EV/EBIT Ratio | 13.59 | 14.49 | 9.39 | 26.74 | 1.48 | 4.93 |
EV/FCF Ratio | 29.01 | - | 20.75 | - | 1.84 | 5.27 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
Debt / EBITDA Ratio | 0.04 | 0.03 | 0.02 | 0.17 | 0.02 | 0.04 |
Debt / FCF Ratio | 0.12 | - | 0.04 | - | 0.02 | 0.05 |
Net Debt / Equity Ratio | -0.56 | -0.60 | -0.66 | -0.72 | -0.91 | -0.89 |
Net Debt / EBITDA Ratio | -12.60 | -11.06 | -9.66 | -23.01 | -2.75 | -3.45 |
Net Debt / FCF Ratio | -37.06 | 190.72 | -23.64 | 5.44 | -3.48 | -3.73 |
Asset Turnover | 0.21 | 0.22 | 0.21 | 0.17 | 0.78 | 0.73 |
Inventory Turnover | 2.48 | 2.66 | 2.25 | 1.99 | 5.41 | 3.33 |
Quick Ratio | 9.93 | 8.92 | 9.06 | 10.57 | 7.76 | 4.53 |
Current Ratio | 11.20 | 9.88 | 9.91 | 11.53 | 8.20 | 5.14 |
Return on Equity (ROE) | 3.62% | 5.62% | 7.85% | 4.51% | 31.85% | 36.06% |
Return on Assets (ROA) | 1.87% | 2.61% | 3.62% | 1.41% | 19.45% | 20.29% |
Return on Invested Capital (ROIC) | 6.70% | 10.75% | 17.64% | 12.52% | 318.80% | 229.74% |
Return on Capital Employed (ROCE) | 3.20% | 4.50% | 6.20% | 2.60% | 32.40% | 25.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.68% | 4.40% | 6.16% | 3.37% | 21.47% | 11.55% |
FCF Yield | 1.51% | -0.25% | 2.22% | -9.49% | 19.76% | 11.82% |
Dividend Yield | 4.02% | 3.20% | 5.02% | 2.44% | 11.84% | 4.14% |
Payout Ratio | 114.23% | 88.61% | 76.92% | 292.78% | 18.20% | 14.08% |
Buyback Yield / Dilution | -0.51% | -0.03% | 0.02% | 0.07% | -5.96% | -25.16% |
Total Shareholder Return | 3.51% | 3.17% | 5.05% | 2.52% | 5.88% | -21.01% |